Actions
(8.84 KB, 315x315)
> HUMA
If HUMA = Humira
Humira treats illnesses caused by malnutrition and toxic food/beverage additives.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The company's primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
It developed Skyrizi ($5 billion in 2022 revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases. Its other major products include Botox ($5 billion in 2022 revenues), Imbruvica to treat cancer ($4.5 billion in 2022 revenues), Rinvoq to treat arthritis ($2.5 billion in 2022 revenues), Venclexta to treat leukemia and lymphoma ($2 billion in annual revenues), Vraylar to treat schizophrenia and bipolar disorder ($2 billion in 2022 revenues), and Mavyret to treat Hepatitis C ($1.5 billion in 2022 revenues).[1] The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.[1][2]
In 2023, Humira began facing competition from a biosimilar developed by Amgen. The company is also developing a drug for Parkinson's disease that could be a blockbuster drug in 2027 and is awaiting approval from the Food and Drug Administration for epcoritamab, a blood-cancer therapy under development in partnership with Genmab.[3]
The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie," intended as a reference to a Latin root meaning "life."
https://en.wikipedia.org/wiki/AbbVie